

## Seth Flaum

PARTNER

Technology  
Transactions  
New York

sflaum@wsgr.com  
212-453-2870



### FOCUS AREAS

Biotech  
Corporate  
Emerging Companies and  
Venture Capital  
Israel  
Life Sciences  
Medical Devices  
Technology Transactions

### HIGHLIGHTS

- Life Sciences Expertise**  
Seth represents pharmaceutical, biotechnology, medical device, diagnostic, and other technology-based companies in a wide range of strategic transactions and corporate matters.
- Extensive In-House Transactional Experience**  
Seth has more than 16 years of experience serving as in-house counsel at a global pharmaceutical company, where he advised on an array of strategic transactions and managed a team of lawyers and business professionals responsible for implementing intellectual property and business development transactions.

### EXPERIENCE

Seth Flaum is a partner in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the technology transactions practice. With more than 25 years of broad transactional experience, he represents life sciences companies in a wide range of strategic transactions and corporate matters.

Prior to joining the firm, Seth was the executive associate general counsel for Daiichi Sankyo, Inc., a global pharmaceutical company based in Japan, where he trained and managed a team of lawyers and business professionals responsible for implementing the company's global business development transactions. In this role, Seth counseled on strategic transactions, structuring, negotiating, and drafting strategic collaboration agreements, licensing agreements, research and development agreements, co-promotion agreements, commercialization agreements, option agreements, material transfer agreements, clinical trial agreements, CRO agreements, distribution agreements, manufacturing and supply agreements, and other transactions. He also has experience with public and private M&A transactions, and has advised on antitrust issues and filings, FINRA inquiries, SEC filings, and corporate governance matters.

Before joining Daiichi Sankyo, Seth was a senior associate at Ullman, Shapiro & Ullman, LLP in New York. Previously, he was general counsel at H&H Bagels, corporate counsel at Thompson Medical Company and Slim Fast Foods Company, and an associate at D'Erasmus, Shure & Perez in Rockville, Maryland.

### CREDENTIALS

#### Education

- J.D., Loyola Law School, 1994
- B.S., Finance, New York University Leonard N. Stern School of Business, 1991

## Admissions

- State Bar of New Jersey
- State Bar of New York

## MATTERS

---

### Illustrative Representations

#### Pharmaceutical and Diagnostic Collaboration Agreements

- **PaciraBioSciences** on its license agreement with **AmacaThera** for AMT-143, an investigational long-acting formulation of the non-opioid analgesic ropivacaine for postsurgical pain control
- **Revival Healthcare Capital** on its strategic partnership with **Olympus Corporation** aimed at harnessing external innovation to accelerate development and market entry for an endoluminal robotics platform initially targeting gastrointestinal treatments
- **Cyrano Therapeutics** on its option agreement with **KYORIN Pharmaceuticals** for CYR-064, a novel treatment for hyposmia
- **Cimeio Therapeutics** on its research collaboration with **Kyowa Kirin**
- **Aytu BioPharma** on its exclusive collaboration, distribution, and supply agreement with **Lupin Pharma Canada Ltd**
- **Ripple Therapeutics** on its collaboration and option-to-license agreement with **AbbVie**
- **BigHat Biosciences** on its research collaboration with **AbbVie**
- **Related Sciences** on its drug discovery collaboration with **Charles River**
- **Daiichi Sankyo** on its global development and commercialization collaboration with **AstraZeneca** for TROP2-directed antibody drug conjugate (ADC) DS-1062\*
- **Daiichi Sankyo** on its strategic coalition with **CRO Syneos Health** to develop an ADC oncology pipeline\*
- **Daiichi Sankyo** on its global development and commercialization collaboration with **AstraZeneca** for HER2-directed ADC DS-8201 (**Enhertu**)\*
- **Daiichi Sankyo** on its clinical trial combination agreement with **Merck** for DS-1062 and **Keytruda**® and with **Bristol-Myers Squibb** for DS-8201 (**Enhertu**) and **Opdivo**®\*
- **Daiichi Sankyo** on its strategic collaboration in Japan with **Kite Pharma Inc.** for a cell therapy product (**Yescarta**)\*
- **Daiichi Sankyo** on multiple collaboration agreements with **Portola Pharmaceuticals** and with **Perosphere** (acquired by **AMAG**) for factor Xa reversal agents\*
- **Daiichi Sankyo** on its strategic collaboration and co-promotion agreement with **AstraZeneca** for a small molecule product for opioid-induced constipation (**Movantik**)\*
- **Daiichi Sankyo** on its strategic collaboration and option agreement with **Amplimmune** (acquired by **AstraZeneca**) for an immune modulation therapy\*
- **Daiichi Sankyo** on its exclusive licensing agreement in Japan with **Coherus Biosciences** for select biosimilars\*
- **Daiichi Sankyo** on multiple exclusive worldwide licensing agreements with **ArQule** (acquired by **Merck**) for small molecule oncology products\*
- **Daiichi Sankyo** on its authorized generic distribution agreements with **Ranbaxy Pharmaceuticals** and **Sun Pharmaceuticals**\*
- **Daiichi Sankyo** on its global collaboration with **Invivoscribe** and other prominent diagnostic companies for companion diagnostics\*
- **Daiichi Sankyo** on its research collaboration with **DarwinHealth**\*
- **Daiichi Sankyo** on its multiple alliance agreements with **Sanford-Burnham Medical Research Institute**\*
- **Venture Science Laboratories** on its drug discovery research collaboration with **University of California San Francisco (UCSF)** to develop novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases\*

#### Mergers and Acquisitions and Divestitures

- **IVIVA** on its acquisition by **United Therapeutics**
- **Plexxikon** on its sale of a portfolio of small molecule oncology therapeutics and other assets to **Opna Bio**\*
- **Daiichi Sankyo** on the divestiture of its pharmaceutical packaging plant and laboratory to **Sharp Packaging Services**, a division of **UDG Healthcare**\*
- **Daiichi Sankyo** on its acquisition of **Ambit Biosciences**\*
- **Daiichi Sankyo** on its sale of **Ranbaxy Laboratories** to **Sun Pharmaceuticals**\*
- **Daiichi Sankyo** on its acquisition of **Plexxikon**\*

*\*Denotes experience prior to joining Wilson Sonsini in 2022.*

